title: Different patterns of HIV-1 DNA after therapy discontinuation.
abstract: BACKGROUND
  By persisting in infected cells for a long period of time, proviral HIV-1 DNA can represent an alternative viral marker to RNA viral load during the follow-up of HIV-1 infected individuals. In the present study sequential blood samples of 10 patients under antiretroviral treatment from 1997 with two NRTIs, who refused to continue any antiviral regimen, were analyzed for 16-24 weeks to study the possible relationship between DNA and RNA viral load.
  
  
  METHODS
  The amount of proviral DNA was quantified by SYBR green real-time PCR in peripheral blood mononuclear cells from a selected group of ten patients with different levels of plasmatic viremia (RNA viral load).
  
  
  RESULTS
  Variable levels of proviral DNA were found without any significant correlation between proviral load and plasma HIV-1 RNA levels. Results obtained showed an increase or a rebound in viral DNA in most patients, suggesting that the absence of therapy reflects an increase and/or a persistence of cells containing viral DNA.
  
  
  CONCLUSIONS
  Even though plasma HIV RNA levels remain the basic parameter to monitor the intensity of viral replication, the results obtained seem to indicate that DNA levels could represent an adjunct prognostic marker in monitoring HIV-1 infected subjects.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. mariacarla.re@unibo.it
authors.forename: Maria Carla
authors.initials: MC
authors.lastname: Re
authors.forename: Francesca
authors.initials: F
authors.lastname: Vitone
authors.forename: Laura
authors.initials: L
authors.lastname: Sighinolfi
authors.forename: Pasqua
authors.initials: P
authors.lastname: Schiavone
authors.forename: Florio
authors.initials: F
authors.lastname: Ghinelli
authors.forename: Davide
authors.initials: D
authors.lastname: Gibellini
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers; D004279:DNA, Viral / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D004279:DNA, Viral; D012367:RNA, Viral